- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07942766
A Study of HW201877 Capsules for Participants With Moderate to Severe Active Inflammatory Bowel Disease (IBD)
A Phase IIa, Open-label, Multicenter Clinical Study to Evaluate the Efficacy and Safety of HW201877 Capsule in the Treatment of Moderate to Severe Active Inflammatory Bowel Disease (IBD)
This is a Phase IIa, open-label, multicenter clinical trial that plans to enroll approximately 20 patients each with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) who have had an inadequate response, loss of response, or intolerance to prior therapies. Participants will receive 12 weeks of the investigational study drug to provide a preliminary assessment of its efficacy and safety.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Lifei Liu
- Número de telefone: 86-27-87173753
- E-mail: liulifei@renfu.com.cn
Locais de estudo
-
-
Hubei
-
Wuhan, Hubei, China, 430060
- Renmin hospital of Wuhan University
-
Contato:
- Ying Chen
- Número de telefone: 86-27-88237069
- E-mail: 3375565387@qq.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Aged 18 to 75 years (inclusive).
- Body Mass Index (BMI) ≥18 kg/m^2 at screening.
- Participants must have been diagnosed with ulcerative colitis or Crohn's disease at least 3 months prior to the start of screening, and confirmed by endoscopy and histology at screening.
- Meeting one of the criteria for moderate to severe active disease.
- Participants have had an inadequate response, loss of response, or intolerance to at least one conventional therapy and/or advanced therapy, or are unable to receive these treatments for other reasons.
- Female participants of childbearing potential must have a negative pregnancy test and must not be breastfeeding; male and female participants must not plan to become pregnant or father a child throughout the clinical study period and for 3 months after the last dose, and must agree to use medically accepted reliable contraceptive methods during the study period and for 3 months after the last dose.
- Fully understand the study, voluntarily sign the informed consent form, and be able to comply with the study procedures and follow-up examination requirements.
Exclusion Criteria:
- Presence of any of the following cohort-specific conditions (as applicable to the enrolled cohort):
Cohort 1 (UC patients): Ulcerative colitis with rectal involvement only (disease extent limited to within 10 cm from the anal verge); Cohort 2 (CD patients): Presence of fistulas (excluding perianal fistulas), perianal abscess (except those without active symptoms after incision and drainage), extensive small bowel resection (>100 cm), or short bowel syndrome, where efficacy cannot be assessed by CDAI/SES-CD.
-
Evidence of or clinical suspicion of other active gastrointestinal inflammatory diseases including: indeterminate colitis (IBDU), intestinal Behçet's disease, colitis ischaemic, radiation colitis, drug-induced enteropathy, enteritis infectious, diverticulitis-associated colitis, etc.
-
Presence of symptomatic intestinal strictures (including those with pre-stenotic dilation and obstructive symptoms), abdominal abscess, fulminant colitis and toxic megacolon, intestinal perforation.
-
Participants who have previously undergone intestinal surgery or who may require surgical treatment during the study (including but not limited to: colostomy/ileostomy, total proctocolectomy, partial colectomy).
-
Long-term exclusive enteral nutrition or parenteral nutrition prior to screening.
-
Endoscopic findings at screening revealing gastrointestinal dysplasia (atypical hyperplasia)/cancer, except for completely resected low-grade dysplasia.
-
Active Clostridium difficile infection or other active intestinal infection within 30 days prior to baseline assessment; or positive Clostridium difficile toxin assay or other enteric pathogen screening within 30 days prior to baseline assessment with infection-related clinical symptoms, except for simple intestinal colonization (without evidence of infection).
-
Participants who currently have or have a history of any of the following infections:
- Clinically significant infection within 1 month prior to screening;
- Any infection requiring antimicrobial therapy within 2 weeks prior to screening;
- Any other history of infection that the investigator believes may be exacerbated by participation in this study.
-
Based on interferon-gamma release assay (e.g., QuantiFERON®-TB Gold test, T-SPOT®.TB, etc.) results, clinical symptoms, and/or chest imaging findings, the participant is judged to possibly have active Mycobacterium tuberculosis (TB) infection.
-
At screening, positive hepatitis B test results, positive Hepatitis C Virus Antibody (HCV Ab), positive Human Immunodeficiency Virus Antibody (HIV Ab), positive Treponema pallidum Antibody (TP Ab).
-
Any congenital or acquired immunodeficiency (e.g., HIV infection, organ transplantation, etc.)
-
Use of any drug or therapeutic measure prohibited by the protocol.
-
Malignancy within 5 years prior to screening (except locally excised non-melanoma skin cancer and radically treated cervical carcinoma in situ); existing non-melanoma skin cancer must be excised prior to enrollment.
-
Any significant laboratory finding will result in exclusion from the study.
-
Clinically significant electrocardiogram abnormalities, such as QTc interval prolongation (male > 450 ms, female > 470 ms) (QTcF = QT/(RR^0.33)), long QT syndrome, etc.
-
History of moderate to severe cardiac failure congestive (New York Heart Association [NYHA] functional class ≥ III), cerebrovascular or cardiovascular events, or severe bleeding events within 3 months prior to screening, which in the investigator's judgment makes the participant unsuitable for participation in the clinical study.
-
Severe, progressive, or uncontrolled cardiovascular, cerebrovascular, hepatic, renal, pulmonary, gastrointestinal, ophthalmic, hematopoietic, endocrine, neurological, psychiatric, or other abnormalities that, in the investigator's assessment, make the participant unsuitable for enrollment in this study.
-
Pregnant or breastfeeding (pregnancy is defined as the state from conception until termination of pregnancy).
-
Allergy to the investigational product or any ingredient in the investigational product.
-
History of alcohol abuse (consumption of 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine) or drug abuse within one year prior to screening.
-
Total blood donation exceeding 500 mL within 8 weeks prior to the first dose, or planned blood donation during the study period.
-
Conditions that, in the investigator's judgment, may affect the safety and efficacy evaluation of the investigational product.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: HW201877
|
HW201877 oral capsule,12W |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Cohort 1 • Proportion of participants achieving clinical remission based on the modified Mayo score at Week 12;
Prazo: At week 12
|
At week 12
|
|
Cohort 2 Co-primary endpoints: • Proportion of participants achieving symptomatic remission at Week 12;
Prazo: At week 12
|
At week 12
|
|
Cohort 2 Co-primary endpoints: • Proportion of participants achieving endoscopic response at Week 12.
Prazo: At week 12
|
At week 12
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Cohort 1 • Proportion of participants achieving endoscopic response at Week 12;
Prazo: at week 12
|
at week 12
|
|
Cohort 1 • Proportion of participants achieving histologic remission at Week 12;
Prazo: at week 12
|
at week 12
|
|
Cohort 2 • Proportion of participants achieving symptomatic response at each visit;
Prazo: at week 12
|
at week 12
|
|
Cohort 2 • Change from baseline in CDAI score at each visit;
Prazo: at week 12
|
at week 12
|
|
Cohort 2 • Change from baseline in total score of Inflammatory Bowel Disease Questionnaire (IBDQ) at each visit.
Prazo: at week 12
|
at week 12
|
|
Safety Endpoints • Incidence of AEs and SAEs during the study;
Prazo: at week 12
|
at week 12
|
|
Safety Endpoints • Incidence of discontinuation of study treatment due to AEs and SAEs during the study;
Prazo: at week 12
|
at week 12
|
|
Safety Endpoints • Incidence of AEs and SAEs leading to withdrawal from the study during the study;
Prazo: at week 12
|
at week 12
|
Colaboradores e Investigadores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- HW201877-201
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .